2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2432

Peripartum Issues in the Inflammatory Arthritis (IA) Patient: A Survey of the Rapport (Rheumatoid Arthritis Pharmacovigilence Program and Outcomes Research in New Therapies) Registry
Abstract Number: 2433

Pregnancy Outcomes in Undifferentiated Connective Tissue Disease- a Single Academic Center’s Experience
Abstract Number: 2434

Obstetric Outcomes in Women with Takayasu Arteritis: Results from Nationwide Inpatient Sample Database 2003-2011
Abstract Number: 2435

Pregnancy Outcomes Among Women with Rare Autoimmune Diseases
Abstract Number: 2436

The Impact of Different Classes of Lupus Nephritis on Maternal and Fetal Outcomes
Abstract Number: 2437

Analysis of Occurrence of Small for Gestational Age Infants in Women with Systemic Lupus Erythematosus
Abstract Number: 2438

Risk and Severity of Adverse Pregnancy Outcomes in Women with Systemic Sclerosis in Taiwan
Abstract Number: 2439

A Description of Contraception Practices in the Ohio State University Lupus Cohort
Abstract Number: 2440

Outcomes of Pregnancy Complicated By ANCA-Associated Vasculitis: A Retrospective Review
Abstract Number: 2441

Needs and Barriers to Pregnancy Counselling in Women with SLE
Abstract Number: 2442

Familial Mediterranean Fever Associated Infertility and Underlying Factors with Fertility
Abstract Number: 2443

Trends in the Incidence of Lymphomas and Leukemias in Patients with Rheumatoid Arthritis in Spain: An Observational Cohort Study of Hospital Discharges from 1999 to 2015
Abstract Number: 2444

The Risk of Solid Cancers in Patients with Rheumatoid Arthritis Exposed to Biologic Dmards with/without Prior Cancers
Abstract Number: 2445

The Effect of Biologic Agents on Hemoglobin Levels of Patients with Rheumatoid Arthritis
Abstract Number: 2446

The Combined Use of Folic Acid Influenced the Time until the Development of Lymphoproliferative Disorders in Patients with Rheumatoid Arthritis during Treatment with Methotrexate

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].